Given the ongoing clinical development and anticipated availability of anti-TIGIT antibodies, combining BCMA-CAR-T therapy with TIGIT blockade may represent a promising strategy to improve clinical outcomes for MM patients. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.